Aptose Biosciences Past Earnings Performance
Past criteria checks 0/6
Aptose Biosciences's earnings have been declining at an average annual rate of -10.2%, while the Biotechs industry saw earnings growing at 16.6% annually.
Key information
-10.2%
Earnings growth rate
5.8%
EPS growth rate
Biotechs Industry Growth | 51.1% |
Revenue growth rate | n/a |
Return on equity | -34,431.4% |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation
Mar 26We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate
Dec 08We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate
Aug 05We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully
Apr 02Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth
Sep 30Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling
Feb 07Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?
Jan 03We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate
Nov 29Jotin Marango Is The Senior VP & Chief Business Officer of Aptose Biosciences Inc. (TSE:APS) And They Just Sold 26% Of Their Shares
Jul 11Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling
Jun 27Revenue & Expenses Breakdown
How Aptose Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -47 | 14 | 34 |
31 Dec 23 | 0 | -51 | 16 | 37 |
30 Sep 23 | 0 | -49 | 16 | 34 |
30 Jun 23 | 0 | -48 | 16 | 33 |
31 Mar 23 | 0 | -44 | 16 | 30 |
31 Dec 22 | 0 | -42 | 15 | 28 |
30 Sep 22 | 0 | -56 | 15 | 42 |
30 Jun 22 | 0 | -58 | 15 | 43 |
31 Mar 22 | 0 | -61 | 16 | 45 |
31 Dec 21 | 0 | -65 | 19 | 46 |
30 Sep 21 | 0 | -56 | 21 | 35 |
30 Jun 21 | 0 | -58 | 23 | 35 |
31 Mar 21 | 0 | -60 | 29 | 32 |
31 Dec 20 | 0 | -55 | 26 | 29 |
30 Sep 20 | 0 | -48 | 23 | 26 |
30 Jun 20 | 0 | -42 | 20 | 23 |
31 Mar 20 | 0 | -32 | 14 | 19 |
31 Dec 19 | 0 | -26 | 10 | 17 |
30 Sep 19 | 0 | -25 | 10 | 16 |
30 Jun 19 | 0 | -24 | 9 | 15 |
31 Mar 19 | 0 | -28 | 9 | 19 |
31 Dec 18 | 0 | -29 | 10 | 19 |
30 Sep 18 | 0 | -26 | 9 | 17 |
30 Jun 18 | 0 | -23 | 9 | 14 |
31 Mar 18 | 0 | -15 | 8 | 8 |
31 Dec 17 | 0 | -12 | 6 | 6 |
30 Sep 17 | 0 | -11 | 5 | 6 |
30 Jun 17 | 0 | -12 | 6 | 6 |
31 Mar 17 | 0 | -14 | 6 | 8 |
31 Dec 16 | 0 | -14 | 6 | 8 |
30 Sep 16 | 0 | -15 | 7 | 8 |
30 Jun 16 | 0 | -14 | 7 | 7 |
31 Mar 16 | 0 | -12 | 7 | 6 |
01 Jan 16 | 0 | -12 | 8 | 5 |
30 Sep 15 | 0 | -9 | 7 | 4 |
31 Dec 14 | 0 | -12 | 8 | 4 |
31 May 14 | 0 | -10 | 6 | 2 |
28 Feb 14 | 0 | -7 | 4 | 3 |
30 Nov 13 | 0 | -6 | 3 | 3 |
Quality Earnings: APS is currently unprofitable.
Growing Profit Margin: APS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APS is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare APS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: APS has a negative Return on Equity (-34431.39%), as it is currently unprofitable.